Back to search
FDAFDA · Food and drugs·Recall number D-0561-2022

HARD DAWN, Rise and Shine capsules, 500 mg, packaged in 10-count blisters per carton, Made in Malaysia, UPC 680044 364926, ASIN: B077XCCL59

Published February 16, 2022 · Recall initiated: January 28, 2022

Summary

FDA records drug Class I recall D-0561-2022, published February 16, 2022 and initiated January 28, 2022. Recalling firm: Esupplementsales, LLC; Status: Terminated; Reported quantity: 500 cartons; Lot: Lot: 2107, Exp July 2024. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without an Approved NDA/ANDA: Firm was informed by Amazon that analytical testing showed the presence of tadalafil. Tadalafil is a FDA approved drug, making this product an unapproved drug.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Esupplementsales, LLC
Distributor
Nationwide in the USA via Amazon at www.amazon.com
Lot
Lot: 2107, Exp July 2024
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was HARD DAWN, Rise and Shine capsules, 500 mg, packaged in 10-count blisters per carton, Made in Malaysia, UPC 680044 364926, ASIN: B077XCCL59 recalled?

Yes. FDA published recall D-0561-2022 on February 16, 2022. Reported hazard: Marketed Without an Approved NDA/ANDA: Firm was informed by Amazon that analytical testing showed the presence of tadalafil. Tadalafil is a FDA approved drug, making this product an unapproved drug.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release